<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2707200128
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CLOGREL 75 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CLOPIDOGREL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        75
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        118.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AJA PHARMACEUTICAL INDUSTRIES" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1916]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B01AC04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">Clogrel belongs to a group of medicines called antiplatelet medicinal products. Platelets are very small structures in the blood, which clump together during<br />blood clotting. By preventing this clumping, antiplatelet medicinal products reduce the chances of blood clots forming (a process called thrombosis).<br />Clogrel is taken by adults to prevent blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead<br />to atherothrombotic events (such as stroke, heart attack, or death).<br />&nbsp; &nbsp; &nbsp; &bull; You have been prescribed Clogrel to help prevent blood clots and reduce the risk of these severe events because:<br />&nbsp; &nbsp; &nbsp; &bull; You have a condition of hardening of arteries (also known as atherosclerosis), and<br />&nbsp; &nbsp; &nbsp; &bull; You have previously experienced a heart attack, stroke or have a condition known as peripheral arterial disease, or<br />&nbsp; &nbsp; &nbsp; &bull; You have experienced a severe type of chest pain known as &lsquo;unstable angina&rsquo; or &lsquo;myocardial infarction&rsquo; (heart attack). For the treatment of this condition your doctor may have placed a stent in the blocked or narrowed artery to restore effective blood flow. You should also be given acetylsalicylic acid (a substance present in many medicines used to relieve pain and lower fever as well as to prevent blood clotting) by<br />your doctor.<br />&nbsp; &nbsp; &nbsp; &nbsp;&bull; You have an irregular heartbeat, a condition called &lsquo;atrial fibrillation&rsquo;, and you cannot take medicines known as &lsquo;oral anticoagulants&rsquo; (vitamin K antagonists) which prevent new clots from forming and prevent existing clots from growing. You should have been told that &lsquo;oral anticoagulants&rsquo; are more effective than acetylsalicylic acid or the combined use of Clogrel and acetylsalicylic acid for this condition. Your doctor should have prescribed Clogrel plus acetylsalicylic acid if you cannot take &lsquo;oral anticoagulants&rsquo; and you do not have a risk of major bleeding.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify"><u><strong>Do not take Clogrel</strong></u><br />If you are allergic (hypersensitive) to clopidogrel, soya oil, peanut oil or any of the other ingredients of this medicine (listed in section 6).<br />&nbsp; &nbsp; &bull; If you have a medical condition that is currently causing bleeding such as a stomach ulcer or bleeding within the brain.<br />&nbsp; &nbsp; &bull; If you suffer from severe liver disease.<br />&nbsp; &nbsp; &bull; If you think any of these apply to you, or if you are in any doubt at all, consult your doctor before taking Clogrel.<br /><u><strong>Warnings and precautions</strong></u><br />If any of the situations mentioned below apply to you, you should tell your doctor before taking Clogrel:<br />&nbsp; &nbsp;&bull; If you have a risk of bleeding such as:<br />&nbsp;&nbsp; &bull; a medical condition that puts you at risk of internal bleeding (such as a stomach ulcer)<br />&nbsp;&nbsp; &bull; a blood disorder that makes you prone to internal bleeding (bleeding inside any tissues, organs or joints of your body).<br />&nbsp; &nbsp;&bull; a recent serious injury</p><p style="text-align:justify">&nbsp; &nbsp;&bull; a recent surgery (including dental).<br />&nbsp; &nbsp;&bull; a planned surgery (including dental) in the next seven days.<br />&nbsp; &nbsp;&bull; If you have had a clot in an artery of your brain (ischaemic stroke) which occurred within the last seven days<br />&nbsp; &nbsp;&bull; If you have kidney or liver disease.<br />&nbsp; &nbsp;&bull; If you have had an allergy or reaction to any medicine used to treat your disease.<br /><strong><u>While you are taking Clogrel:</u></strong><br />&nbsp; &nbsp;&bull; You should tell your doctor if a surgery (including dental) is planned.<br />&nbsp; &nbsp;&bull; You should also tell your doctor immediately if you develop a medical condition (also known as Thrombotic Thrombocytopenic Purpura or TTP) that includes fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes (jaundice) (see section 4 &lsquo;POSSIBLE SIDE EFFECTS&rsquo;).<br />&nbsp; &nbsp;&bull; If you cut or injure yourself, it may take longer than usual for bleeding to stop. This is linked to the way your medicine works as it prevents the ability of blood clots to form. For minor cuts and injuries e.g., cutting yourself, shaving, this is usually of no concern. However, if you are concerned by your bleeding, you should contact your doctor straightaway (see section 4 &lsquo;POSSIBLE SIDE EFFECTS&rsquo;).<br />&nbsp; &nbsp;&bull; Your doctor may order blood tests.<br /><strong><u>Children and adolescents</u></strong><br />Clogrel is not intended for use in children or adolescents.<br /><u><strong>Other medicines and Clogrel</strong></u><br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription. Some other medicines may influence the use of Clogrel or vice versa.</p><p style="text-align:justify">You should specifically tell your doctor if you take:<br />&nbsp; &nbsp; &bull; oral anticoagulants, medicines used to reduce blood clotting,<br />&nbsp; &nbsp; &bull; a non-steroidal anti-inflammatory medicine, usually used to treat painful and/or inflammatory conditions of muscle or joints<br />&nbsp; &nbsp; &bull; heparin or any other injectable medicine used to reduce blood clotting,<br />&nbsp; &nbsp; &bull; omeprazole, esomeprazole or cimetidine, medicines to treat upsetmstomach,<br />&nbsp; &nbsp; &bull; fluconazole, voriconazole, ciprofloxacin, or chloramphenicol, medicines to treat bacterial and fungal infections,<br />&nbsp; &nbsp; &bull; fluoxetine, fluvoxamine, or moclobemide, medicines to treat depression,<br />&nbsp; &nbsp;&bull; carbamazepine, or oxcarbazepine, medicines to treat some forms of epilepsy,<br />&nbsp; &nbsp;&bull; ticlopidine, other antiplatelet agent.<br />If you have experienced severe chest pain (unstable angina or heart attack), you may be prescribed Clogrel in combination with acetylsalicylic acid, a substance<br />present in many medicines used to relieve pain and lower fever. An occasional use of acetylsalicylic acid (no more than 1,000 mg in any 24 hour period) should generally not cause a problem, but prolonged use in other circumstances should be discussed with your doctor.<br /><strong><u>Clogrel with food and drink</u></strong><br />Clogrel may be taken with or without food.<br /><strong><u>Pregnancy and breast-feeding</u></strong><br />It is preferable not to take this product during pregnancy.<br />If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking Clogrel. If you become pregnant while<br />taking Clogrel, consult your doctor immediately as it is recommended not to take clopidogrel while you are pregnant.<br />You should not breastfeed while taking this medicine.<br />&nbsp; &nbsp; &bull; If you are breastfeeding or planning to breastfeed, talk to your doctor before taking this medicine.<br />&nbsp; &nbsp; &bull; If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.<br /><strong><u>Driving and using machines:</u></strong><br />Clogrel is unlikely to affect your ability to drive or to use machines.<br /><strong><u>Important information about some of the ingredients of Clogrel</u></strong><br />Clogrel contains lactose. If you have been told by your doctor that you have intolerance to some sugars (e.g. lactose), contact your doctor before&nbsp;taking this medicine.<br />Clogrel contains soya oil. If you are allergic to peanut or soya, do not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">Always take this medicine exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.<br />If you have experienced severe chest pain (unstable angina or heart attack), your doctor may give you 300 mg of clopidogrel (1 tablet of 300 mg or 4 tablets<br />of 75 mg) once at the start of treatment. Then, the usual dose is one 75 mg tablet of Clogrel per day to be taken orally with or without food, and at the same time each day.<br /><u><strong>You should take Clogrel for as long as your doctor continues to prescribe it.</strong></u><br />If you take more Clogrel than you should<br />&nbsp; &nbsp; &bull; Contact your doctor or the nearest hospital emergency department because of the increased risk of bleeding.<br />If you forget to take Clogrel<br />&nbsp; &nbsp; &bull; If within 12 hours of your usual time, take your tablet straightaway and then take your next tablet at the usual time.<br />&nbsp; &nbsp; &bull; If you forget for more than 12 hours, simply take the next single dose at the usual time. Do not take a double dose to make up for the forgotten tablet.<br />If you stop taking Clogrel<br />Do not stop the treatment unless your doctor tells you so. Contact your doctor or pharmacist before stopping. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">Like all medicines, Clogrel can cause side effects, although not everybody gets them.<br /><u><strong>Contact your doctor immediately if you experience:</strong></u><br />&nbsp; &nbsp; &bull; fever, signs of infection or extreme tiredness. These may be due to rare decrease of some blood cells.<br />&nbsp; &nbsp; &bull; signs of liver problems such as yellowing of the skin and/or the eyes (jaundice), whether or not associated with bleeding which appears under the skin as red pinpoint dots and/or confusion (see section 2 &lsquo;Warnings and precautions&rsquo;).<br />&nbsp; &nbsp; &bull; swelling in the mouth or skin disorders such as rashes and itching, blisters of the skin. These may be the signs of an allergic reaction.<br /><u><strong>The most common side effect reported with Clogrel is bleeding.</strong></u><br />Bleeding may occur as bleeding in the stomach or bowels, bruising, haematoma (unusual bleeding or bruising under the skin), nose bleed, blood in<br />the urine. In a small number of cases, bleeding in the eye, inside the head, the lung or the joints has also been reported.<br /><u><strong>If you experience prolonged bleeding when taking Clogrel</strong></u><br />If you cut or injure yourself, it may take longer than usual for bleeding to stop. This is linked to the way your medicine works as it prevents the ability of<br />blood clots to form. For minor cuts and injuries, e.g. cutting yourself shaving, this is usually of no concern. However, if you are concerned by your bleeding, you should contact your doctor straightaway (see section 2 &lsquo;Warnings and precautions&rsquo;).<br /><strong><u>Other side effects reported with Clogrel are:</u></strong></p><p style="text-align:justify">&nbsp; &nbsp; Common side effects (may affect up to 1 in 10 people): Diarrhoea, abdominal pain, indigestion or heartburn.<br />&nbsp; &nbsp; Uncommon side effects (may affect up to 1 in 100 people): Headache, stomach ulcer, vomiting, nausea, constipation, excessive gas in stomach or intestines, rashes, itching, dizziness, sensation of tingling and numbness.<br />&nbsp; &nbsp; Rare side effect (may affect up to 1 in 1000 people): Vertigo.<br />&nbsp; &nbsp; Very rare side effects (may affect up to 1 in 10,000 people): Jaundice; severe abdominal pain with or without back pain; fever, breathing difficulties sometimes associated with cough; generalised allergic reactions (for example, overall sensation of heat with sudden general discomfort until fainting); swelling in the mouth; blisters of the skin; skin allergy; sore mouth (stomatitis); decrease in blood pressure; confusion; hallucinations; joint pain; muscular pain; changes in taste of food.<br /><strong><u>Immune system disorders:</u></strong><br />Insulin autoimmune syndrome, which can lead to severe hypoglycemia,&nbsp;particularly in patients with HLA DRA4 subtype (more frequent in the Japanese population)*<br />In addition, your doctor may identify changes in your blood or urine test results.<br /><u><strong>Reporting of side effects</strong></u><br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in leaflet below. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the pack, Do not store above 30&deg;C.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">The active substance is clopidogrel as hydrogen sulphate. Each film-coated tablet contains 75 mg of clopidogrel.<br />The other ingredients are:<br />&nbsp; &nbsp; &bull; Tablet core: lactose anhydrous, microcrystalline cellulose, crospovidone Type A, glycerol dibehenate, talc.<br />&nbsp; &nbsp; &bull; Tablet coating: polyvinyl alcohol, talc, macrogol 3350, lecithin (soya oil) (E322), titanium dioxide (E171), iron oxide red (E172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Film-coated tablet.
Pink 9 mm round, biconvex, film-coated tablet, engraved with “A1” on one face.
Pack sizes:
Packed in Alu-Alu blister; 30 tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong><br />AJA Pharmaceutical Industries Company, Ltd.<br />Saudi Arabia, Riyadh<br />The Business Gate, Cordoba<br />G Floor, Zone C2,<br /><strong>Manufacturer</strong><br />AJA Pharmaceutical Industries Company, Ltd.<br />Hail Industrial City MODON, Street No 32<br />PO Box 6979, Hail 55414<br />Kingdom of Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 01/2019.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p style="text-align:justify">يتبع كلوقريل مجموعة من الأدوية تسمى المنتجات الطبية المضادة للصفائح الدموية. الصفائح الدموية هي أشكال صغيرة جدا في الدم والتي تتجمع مع بعضها أثناء تجلط الدم. بمنعها هذا التجميع، فإن المنتجات الطبية المضادة للصفائح الدموية تقلل فرص تكوين الجلطات الدموية (العملية التي تسمى الجلطة)</p><p style="text-align:justify">يتم تناول كلوقريل بواسطة الكبار لمنع تجلط الدم (الجلطات) في الأوعية الدموية الصلبة (الشرايين) وهذه العملية تسمى (تجلط الشرايين) والتي يمكن أن تؤدي إلى حالات تجلط في الشرايين مثل (السكتة الدماغية والنوبات القلبية أو الموت).</p><p style="text-align:justify">تم وصف كلوقريل لك للمساعدة في منع تجلط الدم وتقليل مخاطر هذه الحالات الشديدة للأسباب التالية:</p><p style="text-align:justify">&nbsp; &nbsp;&nbsp;&bull; لديك حالة تصلب شرايين؛ ولقد تعرضت لنوبة قلبية في السابق أو سكتة دماغية أو حالة تعرف بمرض الشرايين الطرفية.</p><p style="text-align:justify">&nbsp; &nbsp; &bull; تعرضت لألم حاد في الصدر يعرف بالذبحة الصدرية غير المستقرة أو احتشاء عضلة القلب (الذبحة القلبية). لعلاج هذه الحالات قد يضع طبيبك دعامة في الشريان المسدود أو الضيق ليستعيد تدفق الدم الفعال. يتعين أيضا إعطائك حامض استيل سالسيليك (acetylsalicylic acid) من قبل طبيبك (وهي مادة موجوده في العديد من الأدوية المستخدمة لتخفيف الألم وخفض الحمى وكذلك لمنع تجلط الدم).</p><p style="text-align:justify">&nbsp; &nbsp;&nbsp;&bull; لديك ضربات قلب غير منتظمة وهي حالة تسمى &lt;الرجفان&nbsp;الأذيني&gt; (artial fibrillation) ولاتستطيع تناول أدوية تسمى &lt;مضادات التخثر الفموية أو مضادات فيتامين ك&gt; والتي تمنع تكوين الجلطات الجديدة وتمنع ظهور الجلطات من النمو. يجب إبلاغك بأن&nbsp;&lt;مضادات التخثر الفموية&gt; أكثر فعالية من حامض استيل سالسيليك إذا كنت لاتستطيع تناول أدوية &lt;مضادات التخثر الفموية&gt; وليس لديك&nbsp;المخاطر الرئيسية للنزيف.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong><u>لا تتناول كلوقريل في الحالات التالية:</u></strong></p><p>&nbsp; &nbsp;&nbsp;&bull; إذا كانت لديك حساسية من الكلوبيدوقريل أو زيت الصويا أو زيت الفول السوداني أو أحد مكونات هذا الدواء (المدرجة في القسم 6).</p><p>&nbsp; &nbsp;&nbsp;&bull; إذا كانت لديك ظروف صحية تسبب النزيف مثل قرحة المعدة أو نزيف في المخ.</p><p>&nbsp; &nbsp;&nbsp;&bull; إذا كنت تعاني من مرض كبدي حاد.</p><p>&nbsp; &nbsp;&nbsp;&bull; إذا كنت تعتقد أن أي هذه الحالات تنطبق عليك أو إذا كان لديك أي شك في ذلك، استشر طبيبك قبل تناول كلوقريل.</p><p><strong><u>المحاذير والاحتياطات</u></strong></p><p>إذا كانت أي من الحالات المذكورة أدناه تنطبق عليك يرجى إبلاغ طبيبك قبل تناول كلوقريل:</p><p>&nbsp;&nbsp; &nbsp;&bull; إذا كان لديك مخاطر نزيف مثل:</p><p>&nbsp; &nbsp;&nbsp;&bull; حالة صحية تضعك في خطر النزيف الداخلي (مثل قرحة المعدة).</p><p>&nbsp; &nbsp;&nbsp;&bull; اضطراب الدم يجعلك عرضة للنزيف الداخلي (نزيف داخل أي أنسجة أو أعضاء أو مفاصل في جسمك).</p><p>&nbsp; &nbsp;&nbsp;&bull; إصابة جديدة خطيرة.</p><p>&nbsp; &nbsp;&nbsp;&bull; عملية جراحية جديدة (بما في ذلك الأسنان)</p><p>&nbsp; &nbsp;&nbsp;&bull; عملية جراحية مخطط لها (بما في ذلك الأسنان) في السبعة أيام المقبلة.</p><p>&nbsp; &nbsp;&nbsp;&bull; إذا كان لديك جلطة في شريان في المخ (السكتة الدماغية الإقفارية) (ischaemic stroke) حدثت في آخر سبعة أيام.</p><p>&nbsp; &nbsp;&nbsp;&bull; إذا كان لديك مرض في الكبد أو الكلى.</p><p>&nbsp; &nbsp;&nbsp;&bull; إذا كانت لديك حساسية لأي دواء يستخدم في علاج مرضك.</p><p><u><strong>أثناء تناولك كلوقريل</strong></u></p><p>&nbsp; &nbsp;&nbsp;&bull; يجب إبلاغ طبيبك إذا كنت مخطط لعملية جراحية (بما في ذلك الأسنان).</p><p>&nbsp; &nbsp;&nbsp;&bull; يجب عليك أيضا إبلاغ طبيبك فورا إذا تطورت لديك حالة صحية (المعروف أيضا باسم تخثر نقص الصفيحات الأساسية) (Thrombotic Thrombocytpenic Purpura TTP) الذي يشمل الحمى وكدمات تحت الجلد أو العيون (اليرقان) (انظر للقسم 4, الأعراض الجانبية المحتملة).</p><p>&nbsp; &nbsp;&nbsp;&bull; إذا قطعت أوجرحت نفسك فإنها قد تأخذ وقتا أطول من المعتاد لوقف النزيف خلاف النزيف العادي. وهذا يرتبط بالطريقة التي يعمل بها دوائك ليمنع تكوين الجلطة الدموية. للجروح الإصابات الطفيفة مثل (جرح نفسك أو الحلاقة فهذه غير مثيرة للقلق.مع ذلك إذا كنت قلقا على النزيف يتوجب عليك التواصل مع طبيبك مباشرة (انظر للقسم 4، الأعراض الجانبية المحتملة).</p><p>&nbsp; &nbsp;&nbsp;&bull; قد يطلب طبيبك اختبارات الدم.</p><p><u><strong>الأطفال والمراهقين</strong></u></p><p>يتعين عادة عدم استعمال كلوقريل للأطفال والمراهقين.</p><p><u><strong>الأدوية الأخرى وكلوقريل</strong></u></p><p>أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرا أو ستتناول أي أدوية أخرى بما في ذلك الأدوية التي تتحصل عليها بدون وصفة طبية.</p><p>بعض الأدوية الأخرى قد تؤثر على استخدام كلوقريل أو العكس.</p><p><u><strong>يرجى اخبار طبيبك مباشرة إذا كنت تتناول:</strong></u></p><p>&nbsp; &nbsp;&nbsp;&bull; مضادات التخثر الفموية والأدوية التي تستخدم لتقليل تجلط الدم.</p><p>&nbsp; &nbsp;&nbsp;&bull; الأدوية غير الاستيرودية والمضادة للالتهابات والتي تستخدم عادة لعلاج الحالات المؤلمة أو حالات التهاب العضلات والمفاصل.</p><p>&nbsp; &nbsp;&nbsp;&bull; الهيبارين أو أي دواء آخر عن طريق الحقن ويستخدم لتقليل تجلط الدم.</p><p>&nbsp; &nbsp;&nbsp;&bull; أميبرازول وإيزومبيرزول أو سيميتدين وهي أدوية لعلاج اضطراب المعدة.</p><p>&nbsp; &nbsp; &bull;&nbsp;فلوكونازول وفوريكونازول وسيبروفلوكاسين اوالكلورامفينيكول وهي ادوية لعلاج الاصابات الفطرية والبكتيرية.</p><p>&nbsp; &nbsp;&nbsp;&bull;&nbsp;&nbsp;فلوكستين و فلوفوكسامين او موكلوبيميد وهي ادوية لعلاج الاكتئاب.</p><p>&nbsp; &nbsp;&nbsp;&bull;&nbsp; كارباميزبين أو أوكساربازبين&nbsp;وهي أدوية لعلاج بعض أنواع الصرع.</p><p>&nbsp; &nbsp;&nbsp;&bull;&nbsp; تيكلوبيدين أو عوامل مضادات الصفائح الدموية الأخرى.</p><p>إذا كنت تعاني من ألم حاد بالصدر (الذبحة الصدرية غير المستقرة أو الذبحة القلبية)، يمكن صرف&nbsp;كلوقريل مع حامض استيل سالسيليك وهي مادة موجوده في العديد من الأدوية المستخدمة لتخفيف الألم والحمى. يجب ألا يسبب الأستخدام المتقطع لحامض استيل سالسيليك أي مشكلة ولكن يتعين مناقشة الاستخدام لمدة طويلة مع الطبيب. (لايزيد عن 1000 ملجم خلال 24 ساعة)</p><p><u><strong>&nbsp;كلوقريل مع الطعام والشراب</strong></u></p><p>&nbsp;يمكن تناول كلوقريل مع الطعام أو بدونه.</p><p><strong><u>الحمل والرضاعة</u></strong></p><p>&nbsp;يفضل عدم تناول هذا المنتج اثناء الحمل.</p><p>إذا كنت حاملا أو تعتقدين بأنك حامل فأخبري طبيبك أو الصيدلي قبل تناول كلوقريل. إذا أصبحت حاملا أثناء تناول كلوقريل، استشيري طبيبك فورا حيث أنه من الموصى به عدم تناول كلوقريل أثناء الحمل.</p><p>لاتُرضعي أثناء تناول هذا الدواء.</p><p>إذا كنت مرضعة أو تخططين للرضاعة تحدثي إلى طبيبك قبل تناول كلوقريل.</p><p><u><strong>القيادة واستخدام المعدات</strong></u></p><p>من غير المحتمل أن يؤثر كلوقريل على قدرتك في القيادة أو استخدام المعدات.</p><p><strong><u>معلومات هامة حول بعض مكونات كلوقريل</u></strong></p><p><strong>يحتوي كلوقريل على اللاكتوز.&nbsp;</strong>إذا أخبرك طبيبك بأنك لاتحتمل بعض أنواع السكريات (مثل اللاكتوز)، تواصل مع طبيبك قبل تناول هذا الدواء.</p><p><strong>يحتوي كلوقريل على زيت الصويا،&nbsp;</strong>إذا كانت لديك حساسية من زيت الفول السوداني أو الصويا فلاتتناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>دائما تناول هذا الدواء تماما كما وصفه الطبيب أو الصيدلي. عليك مراجعة طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p>إذا كنت تعاني من ألم حاد في الصدر (الذبحة الصدرية غير المستقرة أو الذبحة القلبية)، يمكن أن يعطيك الطبيب 300 ملجم من كلوبيدوقريل (1 قرص 300 ملجم أو 4 أقراص 75 ملجم) مرة واحدة في بداية العلاج. ثم بعد ذلك الجرعة العادية قرص واحد 75 ملجم كلوقريل في اليوم، يتم تناولها في نفس الوقت كل يوم عن طريق الفم مع أو بدون الطعام.</p><p>عليك تناول كلوقريل طوال المدة التي وصفت من قبل طبيبك.</p><p><strong><u>إذا تناولت كلوقريل أكثر من المقرر</u></strong></p><p>تواصل مع طبيبك أو أذهب إلى قسم الاسعاف في أقرب مستشفى بسبب تزايد مخاطر النزيف.</p><p><strong><u>إذا نسيت تناول كلوقريل</u></strong></p><p>إذا نسيت تناول الجرعة ولكن تذكرت خلال 12 ساعة. تناول الجرعة مباشرة وثم تناول الجرعة التالية في وقتها المعتاد.</p><p>إذا نسيت لأكثر من 12 ساعة، تناول الجرعة التالية بمفردها في وقتها المعتاد. لاتضاعف الجرعة لتعويض الجرعة المنسية.</p><p><strong><u>إذا توقفت عن تناول كلوقريل</u></strong></p><p>لا توقف العلاج إلا إذا اخبرت طبيبك، تواصل مع طبيبك أو الصيدلي قبل التوقف.</p><p><u>إذا كان لديك أسئلة إضافية عن استخدام الدواء اسأل طبيبك أو الصيدلي.</u></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل كافة الأدوية يمكن أن يسبب كلوقريل آثارا جانبية على الرغم من عدم تعرض كل الناس لها.</p><p>تواصل مع طبيبك فورا إذا عانيت من التالي:</p><p dir="RTL">&nbsp; &nbsp; &bull; حمى أو علامات التهاب أو ارهاق شديد. هذه قد تكون بسبب الانخفاض النادر لبعض خلايا الدم.</p><p dir="RTL">&nbsp; &nbsp; &bull; علامات لمشاكل في الكبد مثل اصفرار الجلد أو العيون (اليرقان) سواء تزامن أو لم يتزامن مع ذلك نزيف الذي يظهر تحت الجلد في شكل بقع حمراء مدببة، أو/و الشعور بالارتباك (أنظر القسم 2، المحاذير والإحتياطات)</p><p>&nbsp; &nbsp; &bull; تورم الفم أو مشاكل في الجلد مثل الطفح الجلدي والحكة والبثور على الجلد. قد تكون هذه علامات حساسية.</p><p><strong><u>الأثر الجانبي الشائع المسجل مع كلوقريل هو النزيف</u></strong></p><p dir="RTL">النزيف قد يحدث كنزيف في المعدة أو الأمعاء وكدمات وورم دموي (نزيف أو كدمات غير عادية تحت الجلد)، رعاف الأنف ودم في البول. تم تسجيل نزيف في العين وداخل الرأس أوالرئة أو المفاصل في بعض الحالات أيضًا.</p><p dir="RTL"><u><strong>إذا عانيت من نزيف لفترة طويلة خلال تناول كلوقريل</strong></u></p><p dir="RTL">إذا قمت بجرح نفسك فإنه قد يستغرق وقتا أطول من المعتاد ليتوقف النزيف. هذا يتعلق بطريقة عمل دوائك ليمنع تكون الجلطة. للجروح والإصابات الطفيفة مثل ( جرح نفسك خلال الحلاقة فهذه لا تستدعي للقلق ولكن يتوجب عليك إبلاغ طبيبك مباشرة. (أنظر القسم2، المحاذير والاحتياطات).</p><p dir="RTL"><strong>أعراض أخرى:</strong></p><p dir="RTL"><strong>الشائعة </strong><strong>(تصيب ١ من كل ١٠ مريض):</strong></p><p dir="RTL">&nbsp; &nbsp; &bull;&nbsp;إسهال</p><p dir="RTL">&nbsp; &nbsp; &bull; ألم في البطن</p><p dir="RTL">&nbsp; &nbsp; &bull; عسر هضم</p><p dir="RTL">&nbsp; &nbsp; &bull;&nbsp;الشعور بحرقان في المريء</p><p dir="RTL"><strong>غير شائعة (تصيب ١ من كل ١٠٠ مريض):</strong></p><p dir="RTL">&nbsp; &nbsp; &bull; صداع أو دوخة</p><p dir="RTL">&nbsp; &nbsp; &bull;&nbsp;تقرح المعدة، غثيان وقيء، امساك، انتفاخ في البطن والامعاء</p><p dir="RTL">&nbsp; &nbsp; &bull; طفح وحكة</p><p dir="RTL">&nbsp; &nbsp; &bull;&nbsp;الشعور بوخز أو تنميل</p><p dir="RTL"><strong>نادرة (تصيب ١ من كل ١٠٠٠ مريض):</strong></p><p dir="RTL">&nbsp; &nbsp; &bull; دوار</p><p dir="RTL"><strong>نادرة جداً (تصيب ١ من كل ١٠٠٠٠ مريض):</strong></p><p dir="RTL">&nbsp; &nbsp; &bull;&nbsp;يرقان</p><p dir="RTL">&nbsp; &nbsp; &bull;&nbsp;الم حاد في البطن مع أو بدون ألم في الظهر</p><p dir="RTL">&nbsp; &nbsp;&nbsp;&bull; حمى</p><p dir="RTL">&nbsp; &nbsp; &bull;&nbsp;صعوبات التنفس متزامنه أحيانا بالكحة</p><p dir="RTL">&nbsp; &nbsp; &bull; حساسية عامة (مثلا الإحساس الكلي المفاجىء بالحرارة مع عدم الراحة حتى الإغماء)</p><p dir="RTL">&nbsp; &nbsp; &bull; تورم الفم</p><p dir="RTL">&nbsp; &nbsp; &bull;&nbsp;بثور في الجلد أو حساسية الجلد</p><p dir="RTL">&nbsp; &nbsp; &bull; قرحة الفم (التهاب الفم)</p><p dir="RTL">&nbsp; &nbsp; &bull; انخفاض في ضغط الدم</p><p dir="RTL">&nbsp; &nbsp; &bull; الشعور بالارتباك أو الهلوسة</p><p dir="RTL">&nbsp; &nbsp; &bull;&nbsp;الم في المفاصل أو العضلات</p><p dir="RTL">&nbsp; &nbsp; &bull;&nbsp;التغير في حاسة التذوق أو فقدانها</p><p dir="RTL"><u><strong>اضطرابات الجهاز المناعي</strong></u></p><p dir="RTL">متلازمة الإنسولين ذاتي المناعة، والتي من الممكن أن تؤدي إلى إنخفاض شديد في سكر الدم، خاصة عند المرضى الذين لديهم النوع الفرعي HAL DRA4 (أكثر حدوثا في السكان اليابانيين)</p><p dir="RTL">بالإضافة لذلك، قد يحدد طبيبك التغييرات في نتائج اختبار الدم والبول لديك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيداً عن متناول الأطفال.</p><p dir="RTL">لا يستخدم بعد انتهاء الصلاحية كما هو موضح على العلبة.</p><p dir="RTL">لا يخزن في درجة حرارة أكثر من 30 درجة مئوية.</p><p dir="RTL">يجب عدم التخلص من الأدوية عبر مياه الصرف الصحي أو النفايات المنزلية. أسأل الصيدلي عن طريقة التخلص من الأدوية التي لا تحتاج إليها. ستساعد هذه التعليمات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><u><strong>على ماذا يحتوي كلوقريل</strong></u></p><p>المادة الفعالة هي كلوبيدوقريل على شكل هيدروجين سالفيت. يحتوي كل قرص مغلف على 75 ملجم كلوبيدوقريل.</p><p><strong><u>المكونات الأخرى هي:</u></strong></p><p>لب القرص: لاكتوز لامائي، سيليولوز بلوري مجهري، كروسكبيفيدون النوع أ، جليسرول دايبيهنيت، التالك.</p><p>غلاف القرص: كحول بوليفينيل، التالك، ماكروجول 3350، ليسيثن (زيت الصويا (إي 322) ثاني أكسيد التيتانيوم (إي 171) أكسيد الحديد الأحمر (إي 172).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong><u>كيف يبدو كلوقريل ومحتويات العبوة</u></strong></p><p>حزمة أقراص مغلفة بشريط رقيق:</p><p>أقراص وردية دائرية 9مم مغلفة بشريط رقيق، ثنائية التحدب منقوش عليها (A1) في وجه واحد.</p><p><strong><u>أحجاب العبوات:</u></strong></p><p>مغلفة في شريط ألمنيوم، علبة كرتونية: 30 قرص</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>الشركة المصنعة</strong></p><p>شركة آجا للصناعات الدوائية</p><p>المدينة الصناعية مدن بحائل، شارع رقم 32</p><p>حائل 55414، ص.ب. 6979</p><p>المملكة العربية السعودية</p><p><strong>مالك حق التسويق</strong></p><p>شركة آجا للصناعات الدوائية</p><p>المملكة العربية السعودية، الرياض</p><p>بوابة الأعمال، قرطبة</p><p>الدور الأرضي، المنطقة سي-2</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة الطبية بتاريخ: 01/2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CLOGREL 75 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 97.86 mg Clopidogrel Hydrogen Sulphate corresponding to 75 mg clopidogrel.
Excipient(s) with known effect:: Each film-coated tablet contains 78.14 mg lactose anhydrous and 0.29 mg lecithin (contains soya oil) (E322).
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
Pink 9 mm round, biconvex, film-coated tablet, engraved with “A1” on one side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><em>Prevention of atherothrombotic events</em></p><p style="text-align:justify">Clopidogrel is indicated in:</p><ul><li style="text-align:justify">Adult patients suffering from myocardial infarction (from a few days until less than 35 days),ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.</li><li style="text-align:justify">Adult patients suffering from acute coronary syndrome:<ul><li style="text-align:justify">Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid(ASA).</li><li style="text-align:justify">ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.</li></ul></li></ul><p style="text-align:justify"><em>Prevention of atherothrombotic and thromboembolic events in atrial fibrillation</em><br />In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.</p><p style="text-align:justify">For further information please refer to section 5.1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><u>Posology</u><br /><em>Adults and elderly</em><br />Clopidogrel should be given as a single daily dose of 75 mg.</p><p style="text-align:justify">In patients suffering from acute coronary syndrome:</p><ul><li style="text-align:justify">Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction): clopidogrel treatment should be initiated with a single 300-mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily). Since higher doses of ASA were associated with higher bleeding risk it is recommended that the dose of ASA should not be higher than 100 mg. The optimal duration of treatment has not been formally established. Clinical trial data support use up to 12 months, and the maximum benefit was seen at 3 months (see section 5.1).</li><li style="text-align:justify">ST segment elevation acute myocardial infarction: clopidogrel should be given as a single daily dose of 75 mg initiated with a 300-mg loading dose in combination with ASA and with or without thrombolytics. For patients over 75 years of age clopidogrel should be initiated without a loading dose. Combined therapy should be started as early as possible after symptoms start and continued for at least four weeks The benefit of the combination of clopidogrel with ASA beyond four weeks has not been studied in this setting (see section 5.1).</li></ul><p style="text-align:justify">In patients with atrial fibrillation, clopidogrel should be given as a single daily dose of 75 mg. ASA (75-100 mg daily) should be initiated and continued in combination with clopidogrel (see section 5.1).</p><p style="text-align:justify">If a dose is missed:</p><ul><li style="text-align:justify">Within less than 12 hours after regular scheduled time: patients should take the dose immediately and then take the next dose at the regular scheduled time.</li><li style="text-align:justify">For more than 12 hours: patients should take the next dose at the regular scheduled time and should not double the dose.</li></ul><p style="text-align:justify"><em>Paediatric population</em><br />Clopidogrel should not be used in children because of efficacy concerns (see section 5.1).</p><p style="text-align:justify"><em>Renal impairment</em><br />Therapeutic experience is limited in patients with renal impairment (see section 4.4).</p><p style="text-align:justify"><em>Hepatic impairment</em><br />Therapeutic experience is limited in patients with moderate hepatic disease who may have bleeding diatheses (see section 4.4).</p><p style="text-align:justify"><u>Method of administration</u></p><p style="text-align:justify">For oral use<br />It may be given with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substance, soya oil, peanut oil or to any of the excipients listed in section 6.1.
• Severe hepatic impairment.
• Active pathological bleeding such as peptic ulcer or intracranial haemorrhage.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><em>Bleeding and haematological disorders</em></p><p style="text-align:justify">Due to the risk of bleeding and haematological adverse reactions, blood cell count determination and/or other appropriate testing should be promptly considered whenever clinical symptoms suggestive of bleeding arise during the course of treatment (see section 4.8). As with other antiplatelet agents, clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with ASA, heparin, glycoprotein IIb/IIIa inhibitors or non- steroidal anti-inflammatory drugs (NSAIDs) including Cox-2 inhibitors. Patients should be followed carefully for any signs of bleeding including occult bleeding, especially during the first weeks of treatment and/or after invasive cardiac procedures or surgery. The concomitant administration of clopidogrel with oral anticoagulants is not recommended since it may increase the intensity of bleedings (see section 4.5).<br />If a patient is to undergo elective surgery and antiplatelet effect is temporarily not desirable, clopidogrel should be discontinued 7 days prior to surgery. Patients should inform physicians and dentists that they are taking clopidogrel before any surgery is scheduled and before any new medicinal product is taken.<br />Clopidogrel prolongs bleeding time and should be used with caution in patients who have lesions with a propensity to bleed (particularly gastrointestinal and intraocular).<br />Patients should be told that it might take longer than usual to stop bleeding when they take clopidogrel (alone or in combination with ASA), and that they should report any unusual bleeding (site or duration) to their physician.</p><p style="text-align:justify"><em>Thrombotic Thrombocytopenic Purpura (TTP)</em></p><p style="text-align:justify">Thrombotic Thrombocytopenic Purpura (TTP) has been reported very rarely following the use of clopidogrel, sometimes after a short exposure. It is characterised by thrombocytopenia and microangiopathic haemolytic anaemia associated with either neurological findings, renal dysfunction or fever. TTP is a potentially fatal condition requiring prompt treatment including plasmapheresis.</p><p style="text-align:justify"><em>Acquired haemophilia</em></p><p style="text-align:justify">Acquired haemophilia has been reported following use of clopidogrel. In cases of confirmed isolated activated Partial Thromboplastin Time (aPTT) prolongation with or without bleeding, acquired haemophilia should be considered. Patients with a confirmed diagnosis of acquired haemophilia should be managed and treated by specialists, and clopidogrel should be discontinued.</p><p style="text-align:justify"><em>Recent ischaemic stroke</em></p><p style="text-align:justify">In view of the lack of data, clopidogrel cannot be recommended during the first 7 days after acute ischaemic stroke.</p><p style="text-align:justify"><em>Cytochrome P450 2C19 (CYP2C19)</em></p><p style="text-align:justify">Pharmacogenetics: In patients who are poor CYP2C19 metabolisers, clopidogrel at recommended doses forms less of the active metabolite of clopidogrel and has a smaller effect on platelet function. Tests are available to identify a patient&#39;s CYP2C19 genotype.<br />Since clopidogrel is metabolised to its active metabolite partly by CYP2C19, use of medicinal products that inhibit the activity of this enzyme would be expected to result in reduced drug levels of the active metabolite of clopidogrel. The clinical relevance of this interaction is uncertain. As a precaution concomitant use of strong or moderate CYP2C19 inhibitors should be discouraged (see section 4.5 for a list of CYP2C19 inhibitors, see also section 5.2).</p><p style="text-align:justify"><em>Allergic cross-reactivity</em></p><p style="text-align:justify">Patients should be evaluated for history of hypersensitivity to another thienopyridine (such as ticlopidine, prasugrel) since allergic cross-reactivity among thienopyridines has been reported (see section 4.8). Patients who have had previous hypersensitivity to other thienopyridines should be carefully monitored for signs of hypersensitivity to clopidogrel during treatment.</p><p style="text-align:justify"><em>Renal impairment</em></p><p style="text-align:justify">Therapeutic experience with clopidogrel is limited in patients with renal impairment. Therefore clopidogrel should be used with caution in these patients (see section 4.2).</p><p style="text-align:justify"><em>Hepatic impairment</em></p><p style="text-align:justify">Experience is limited in patients with moderate hepatic disease who may have bleeding diatheses. Clopidogrel should therefore be used with caution in this population (see section 4.2).</p><p style="text-align:justify"><em>Galactose intolerance,</em></p><p style="text-align:justify">Lapp lactase deficiency, glucose-galactose malabsorbtion<br />CLOGREL contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p><p style="text-align:justify"><em>Lecithin</em></p><p style="text-align:justify">CLOGREL contains lecithin (soya oil). If a patient is hypersensitive to peanut or soya, this medicine should not be used.<br />The tablet container contains desiccant that should not be swallowed.</p><p style="text-align:justify"><em>Cross-reactions among thienopyridines</em></p><p style="text-align:justify">Thienopyridines may cause mild to severe allergic reactions such as rash, angioedema, or haematological cross-reactions such as thrombocytopaenia and neutropaenia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><em>Oral anticoagulants:</em> the concomitant administration of clopidogrel with oral anticoagulants is not recommended since it may increase the intensity of bleedings (see section 4.4). Although the administration of clopidogrel 75 mg/day did not modify the pharmacokinetics of S-warfarin or International Normalised Ratio (INR) in patients receiving long-term warfarin therapy, coadministration of clopidogrel with warfarin increases the risk of bleeding because of independent effects on hemostasis.</p><p style="text-align:justify"><em>Glycoprotein IIb/IIIa inhibitors:</em> clopidogrel should be used with caution in patients who receive concomitant glycoprotein IIb/IIIa inhibitors (see section 4.4).</p><p style="text-align:justify"><em>Acetylsalicylic acid (ASA):</em> ASA did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation, but clopidogrel potentiated the effect of ASA on collagen-induced platelet aggregation. However, concomitant administration of 500 mg of ASA twice a day for one day did not significantly increase the prolongation of bleeding time induced by clopidogrel intake. A pharmacodynamic interaction between clopidogrel and acetylsalicylic acid is possible, leading to increased risk of bleeding. Therefore, concomitant use should be undertaken with caution (see section 4.4). However, clopidogrel and ASA have been administered together for up to one year (see section 5.1).</p><p style="text-align:justify"><em>Heparin:</em> in a clinical study conducted in healthy subjects, clopidogrel did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation. Co-administration of heparin had no effect on the inhibition of platelet aggregation induced by clopidogrel. A pharmacodynamic interaction between clopidogrel and heparin is possible, leading to increased risk of bleeding. Therefore, concomitant use should be undertaken with caution (see section 4.4).</p><p style="text-align:justify"><em>Thrombolytics</em>: the safety of the concomitant administration of clopidogrel, fibrin or non-fibrin specific thrombolytic agents and heparins was assessed in patients with acute myocardial infarction. The incidence of clinically significant bleeding was similar to that observed when thrombolytic agents and heparin are co- administered with ASA (see section 4.8)</p><p style="text-align:justify"><em>NSAIDs:</em> in a clinical study conducted in healthy volunteers, the concomitant administration of clopidogrel and naproxen increased occult gastrointestinal blood loss. However, due to the lack of interaction studies with other NSAIDs it is presently unclear whether there is an increased risk of gastrointestinal bleeding with all NSAIDs. Consequently, NSAIDs including Cox-2 inhibitors and clopidogrel should be co-administered with caution (see section 4.4).</p><p style="text-align:justify"><em>SSRIs:</em> since SSRIs affect platelet activation and increase the risk of bleeding, the concomitant administration of SSRIs with clopidogrel should be undertaken with caution.&rdquo;</p><p style="text-align:justify"><em>CYP2C8 substrate medicinal products: </em>Clopidogrel has been shown to increase repaglinide exposure in healthy volunteers. In vitro studies have shown the increase in repaglinide exposure is due to inhibition of CYP2C8 by the glucuronide metabolite of clopidogrel. Due to the risk of increased plasma concentrations, concomitant administration of clopidogrel and drugs primarily cleared by CYP2C8 metabolism (e.g., repaglinide, paclitaxel) should be undertaken with caution.</p><p style="text-align:justify"><em>Other concomitant therapy:</em><br />Since clopidogrel is metabolised to its active metabolite partly by CYP2C19, use of medicinal products that inhibit the activity of this enzyme would be expected to result in reduced drug levels of the active metabolite of clopidogrel. The clinical relevance of this interaction is uncertain. As a precaution concomitant use of strong or moderate CYP2C19 inhibitors should be discouraged (see sections 4.4 and 5.2).</p><p style="text-align:justify">Medicinal products that inhibit CYP2C19 include omeprazole and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine, ciprofloxacin, cimetidine, carbamazepine, oxcarbazepine and chloramphenicol.</p><p style="text-align:justify"><em>Proton Pump Inhibitors (PPI):&nbsp;</em>Omeprazole 80 mg once daily administered either at the same time as clopidogrel or with 12 hours between the administrations of the two drugs decreased the exposure of the active metabolite by 45% (loading dose) and 40% (maintenance dose). The decrease was associated with a 39% (loading dose) and 21% (maintenance dose) reduction of inhibition of platelet aggregation. Esomeprazole is expected to give a similar interaction with clopidogrel.</p><p style="text-align:justify">Inconsistent data on the clinical implications of this pharmacokinetic (PK)/pharmacodynamic (PD) interaction in terms of major cardiovascular events have been reported from both observational and clinical studies. As a precaution, concomitant use of omeprazole or esomeprozole should be discouraged (see section 4.4).</p><p style="text-align:justify">Less pronounced reductions of metabolite exposure has been observed with pantoprazole or lansoprazole. The plasma concentrations of the active metabolite was 20% reduced (loading dose) and 14% reduced (maintenance dose) during concomitant treatment with pantoprazole 80 mg once daily. This was associated<br />with a reduction of the mean inhibition of platelet aggregation by 15% and 11%, respectively. These results indicate that clopidogrel can be administered with pantoprazole</p><p style="text-align:justify">There is no evidence that other medicinal products that reduce stomach acid such as H2 blockers (except cimetidine which is a CYP2C19 inhibitor) or antacids interfere with antiplatelet activity of clopidogrel.</p><p style="text-align:justify"><em>Other medicinal products: </em>A number of other clinical studies have been conducted with clopidogrel and other concomitant medicinal products to investigate the potential for pharmacodynamic and pharmacokinetic interactions. No clinically significant pharmacodynamic interactions were observed when clopidogrel was co-administered with atenolol, nifedipine, or both atenolol and nifedipine. Furthermore, the pharmacodynamic activity of clopidogrel was not significantly influenced by the co-administration of phenobarbital or oestrogen.</p><p style="text-align:justify">The pharmacokinetics of digoxin or theophylline were not modified by the co-administration of clopidogrel. Antacids did not modify the extent of clopidogrel absorption.</p><p style="text-align:justify">Data from the CAPRIE study indicate that phenytoin and tolbutamide which are metabolised by CYP2C9 can be safely co-administered with clopidogrel.</p><p style="text-align:justify">Apart from the specific medicinal product interaction information described above, interaction studies with clopidogrel and some medicinal products commonly administered in patients with atherothrombotic disease have not been performed. However, patients entered into clinical trials with clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers, ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><em>Pregnancy</em><br />As no clinical data on exposure to clopidogrel during pregnancy are available, it is preferable not to use clopidogrel during pregnancy as a precautionary measure.<br />Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3).</p><p style="text-align:justify"><em>Pregnancy Category B Breastfeeding</em><br />It is unknown whether clopidogrel is excreted in human breast milk. Animal studies have shown excretion of<br />clopidogrel in breast milk. As a precautionary measure, breast-feeding should not be continued during treatment with CLOGREL.</p><p style="text-align:justify"><em>Fertility</em><br />Clopidogrel was not shown to alter fertility in animal studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clopidogrel has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Clopidogrel has been evaluated for safety in more than 44,000 patients who have participated in clinical studies, including over 12,000 patients treated for 1 year or more. Overall, clopidogrel 75 mg/day was comparable to ASA 325 mg/day in CAPRIE, regardless of age, gender and race. The clinically relevant adverse reactions observed in the CAPRIE, CURE, CLARITY, COMMIT and ACTIVE-A studies are discussed below. In addition to clinical studies experience, adverse reactions have been spontaneously reported.</p><p style="text-align:justify">Bleeding is the most common reaction reported both in clinical studies as well as in post-marketing experience where it was mostly reported during the first month of treatment.<br />In CAPRIE, in patients treated with either clopidogrel or ASA, the overall incidence of any bleeding was 9.3%. The incidence of severe cases was similar for clopidogrel and ASA.</p><p style="text-align:justify">In CURE, there was no excess in major bleeds with clopidogrel plus ASA within 7 days after coronary bypass graft surgery in patients who stopped therapy more than five days prior to surgery. In patients who remained on therapy within five days of bypass graft surgery, the event rate was 9.6% for clopidogrel plus ASA, and 6.3% for placebo plus ASA.</p><p style="text-align:justify">In CLARITY, there was an overall increase in bleeding in the clopidogrel plus ASA group vs. the placebo plus ASA group. The incidence of major bleeding was similar between groups. This was consistent across subgroups of patients defined by baseline characteristics, and type of fibrinolytic or heparin therapy.</p><p style="text-align:justify">In COMMIT, the overall rate of noncerebral major bleeding or cerebral bleeding was low and similar in both groups.<br />In ACTIVE-A, the rate of major bleeding was greater in the clopidogrel + ASA group than in the placebo + ASA group (6.7% versus 4.3%). Major bleeding was mostly of extracranial origin in both groups (5.3% in the clopidogrel + ASA group; 3.5% in the placebo +ASA group), mainly from the gastrointestinal tract (3.5% vs. 1.8%). There was an excess of intracranial bleeding in the clopidogrel + ASA treatment group compared to the placebo + ASA group (1.4% versus 0.8%, respectively).</p><p style="text-align:justify">There was no statistically significant difference in the rates of fatal bleeding (1.1% in the clopidogrel + ASA group and 0.7% in the placebo +ASA group) and haemorrhagic stroke (0.8% and 0.6%, respectively) between groups.</p><p style="text-align:justify">Tabulated list of adverse reactions<br />Adverse reactions that occurred either during clinical studies or that were spontaneously reported are presented in the table below. Their frequency is defined using the following conventions:<br />common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000).<br />not known (cannot be estimated from the available data)<br />Within each system organ class, adverse reactions are presented in order of decreasing seriousness.</p><table border="1" cellspacing="1" cellpadding="1" style="width:565px"><tbody><tr><td style="width:120px"><strong>System Organ Class</strong></td><td style="width:59px"><strong>Common</strong></td><td style="width:116px"><strong>Uncommon</strong></td><td style="width:94px"><strong>Rare</strong></td><td style="width:176px"><strong>Very rare Not known</strong></td></tr><tr><td style="width:120px">Blood and the lymphatic system disorders</td><td style="width:59px">&nbsp;</td><td style="width:116px">Thrombocytopenia, leucopenia, eosinophilia</td><td style="width:94px">Neutropeni a, including severe neutropenia</td><td style="width:176px">Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), aplastic anaemia, pancytopenia, agranulocytosis, severe thrombocytopenia, granulocytopenia, anaemia</td></tr><tr><td style="width:120px">Immune system disorders</td><td style="width:59px">&nbsp;</td><td style="width:116px">&nbsp;</td><td style="width:94px">&nbsp;</td><td style="width:176px">Serum sickness, anaphylactoid reactions cross- reactive drug hypersensitivity among thienopyridines (such as ticlopidine, prasugrel) (see section 4.4)*<br />Insulin autoimmune syndrome, which can lead to severe hypoglycemia, particularly in patients with HLA DRA4 subtype (more frequent in the Japanese population)*</td></tr><tr><td style="width:120px">Psychiatric disorders</td><td style="width:59px">&nbsp;</td><td style="width:116px">&nbsp;</td><td style="width:94px">&nbsp;</td><td style="width:176px">Hallucinations, confusion</td></tr><tr><td style="width:120px">Nervous system disorders</td><td style="width:59px">&nbsp;</td><td style="width:116px">Intracranial bleeding (some cases were reported with fatal outcome), headache, paraesthesia, dizziness</td><td style="width:94px">&nbsp;</td><td style="width:176px">Taste disturbances</td></tr><tr><td style="width:120px">Eye disorders</td><td style="width:59px">&nbsp;</td><td style="width:116px">Eye bleeding (conjunctival, ocular, retinal)</td><td style="width:94px">&nbsp;</td><td style="width:176px">&nbsp;</td></tr><tr><td style="width:120px">Ear and labyrinth disorders</td><td style="width:59px">&nbsp;</td><td style="width:116px">&nbsp;</td><td style="width:94px">Vertigo</td><td style="width:176px">&nbsp;</td></tr><tr><td style="width:120px">Vascular disorders</td><td style="width:59px">Haematoma</td><td style="width:116px">&nbsp;</td><td style="width:94px">&nbsp;</td><td style="width:176px">Serious haemorrhage, haemorrhage of operative wound, vasculitis, hypotension</td></tr><tr><td style="width:120px">Respiratory, thoracic and mediastinal disorders</td><td style="width:59px">Epistaxis</td><td style="width:116px">&nbsp;</td><td style="width:94px">&nbsp;</td><td style="width:176px">Respiratory tract bleeding (haemoptysis, pulmonary haemorrhage), bronchospasm, interstitial pneumonitis, eosinophilic pneumonia</td></tr><tr><td style="width:120px">Gastrointestinal disorders</td><td style="width:59px">Gastrointestinal haemorrhage, diarrhoea, abdominal pain, dyspepsia</td><td style="width:116px">Gastric ulcer and duodenal ulcer, gastritis, vomiting, nausea, constipation, flatulence</td><td style="width:94px">Retroperitoneal haemorrhage</td><td style="width:176px">Gastrointestinal and retroperitoneal haemorrhage with fatal outcome, pancreatitis, colitis (including ulcerative or lymphocytic colitis), stomatitis</td></tr><tr><td style="width:120px">Hepatobiliary disorders</td><td style="width:59px">&nbsp;</td><td style="width:116px">&nbsp;</td><td style="width:94px">&nbsp;</td><td style="width:176px">Acute liver failure, hepatitis, abnormal liver function test</td></tr><tr><td style="width:120px">Skin and subcutaneous tissue disorders</td><td style="width:59px">Bruising</td><td style="width:116px">Rash, pruritus, skin bleeding (purpura)</td><td style="width:94px">&nbsp;</td><td style="width:176px">Bullous dermatitis (toxic epidermal necrolysis, Stevens Johnson Syndrome, erythema multiforme), angioedema, drug- induced hypersensitivity syndrome, drug rash with eosinophilia and systemic symptoms (DRESS) rash erythematous, urticaria, eczema, lichen planus</td></tr><tr><td style="width:120px">Musculoskeletal<br />, connective tissue and bone disorders</td><td style="width:59px">&nbsp;</td><td style="width:116px">&nbsp;</td><td style="width:94px">&nbsp;</td><td style="width:176px">Musculo-skeletal bleeding (haemarthrosis), arthritis, arthralgia, myalgia</td></tr><tr><td style="width:120px">Renal and urinary disorders</td><td style="width:59px">&nbsp;</td><td style="width:116px">Haematuria</td><td style="width:94px">&nbsp;</td><td style="width:176px">Glomerulonephritis, blood creatinine increased</td></tr><tr><td style="width:120px">General disorders and administration site conditions</td><td style="width:59px">Bleeding at puncture site</td><td style="width:116px">&nbsp;</td><td style="width:94px">&nbsp;</td><td style="width:176px">Fever</td></tr><tr><td style="width:120px">Investigations</td><td style="width:59px">&nbsp;</td><td style="width:116px">Bleeding time prolonged, neutrophil count decreased, platelet count decreased</td><td style="width:94px">&nbsp;</td><td style="width:176px">&nbsp;</td></tr></tbody></table><p>* Information related to clopidogrel with frequency &ldquo;not known&rdquo;.</p><p>To report any side effect(s):</p><p>&nbsp;</p><ul><li><strong>&nbsp;Saudi Arabia:</strong><ul><li>&nbsp;The National Pharmacovigilance Centre (NPC)<ul><li><p>&nbsp;Fax: +966-11-205-7662</p></li><li><p>SFDA Call Center: 19999</p></li><li><p>E-mail: npc.drug@sfda.gov.sa</p></li><li><p>Website: https://ade.sfda.gov.sa&nbsp;</p></li></ul></li></ul></li><li><strong>Other GCC Slates:</strong><br />Please contact the relevant competent authority.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Overdose following clopidogrel administration may lead to prolonged bleeding time and subsequent bleeding complications. Appropriate therapy should be considered if bleedings are observed. No antidote to the pharmacological activity of clopidogrel has been found. If prompt correction of prolonged bleeding time is required, platelet transfusion may reverse the effects of clopidogrel.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Pharmacotherapeutic group: platelet aggregation inhibitors excl. heparin, ATC Code: B01AC04.</p><p style="text-align:justify"><em>Mechanism of action</em><br />Clopidogrel is a prodrug, one of whose metabolites is an inhibitor of platelet aggregation. Clopidogrel must be metabolised by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation. The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation. Due to the irreversible binding, platelets exposed are affected for the remainder of their lifespan (approximately 7-10 days) and recovery of normal platelet function occurs at a rate consistent with platelet turnover. Platelet aggregation induced by agonists other than ADP is also inhibited by blocking the amplification of platelet activation by released ADP.</p><p style="text-align:justify">Because the active metabolite is formed by CYP450 enzymes, some of which are polymorphic or subject to inhibition by other medicinal products, not all patients will have adequate platelet inhibition.</p><p style="text-align:justify"><em>Pharmacodynamic effects</em><br />Repeated doses of 75 mg per day produced substantial inhibition of ADP-induced platelet aggregation from the first day; this increased progressively and reached steady state between Day 3 and Day 7. At steady state, the average inhibition level observed with a dose of 75 mg per day was between 40% and 60%. Platelet aggregation and bleeding time gradually returned to baseline values, generally within 5 days after treatment was discontinued</p><p style="text-align:justify"><em>Clinical efficacy and safety</em><br />The safety and efficacy of clopidogrel have been evaluated in 5 double-blind studies involving over 88,000 patients: the CAPRIE study, a comparison of clopidogrel to ASA, and the CURE, CLARITY, COMMIT and ACTIVE-A studies comparing clopidogrel to placebo, both medicinal products given in combination with ASA and other standard therapy.</p><p style="text-align:justify"><em>Recent myocardial infarction (MI), recent stroke or established peripheral arterial disease</em><br />The CAPRIE study included 19,185 patients with atherothrombosis as manifested by recent myocardial infarction (&lt; 35 days), recent ischaemic stroke (between 7 days and 6 months) or established peripheral arterial disease (PAD). Patients were randomised to clopidogrel 75 mg/day or ASA 325 mg/day, and were followed for 1 to 3 years. In the myocardial infarction subgroup, most of the patients received ASA for the first few days following the acute myocardial infarction.</p><p style="text-align:justify">Clopidogrel significantly reduced the incidence of new ischaemic events (combined end point of myocardial infarction, ischaemic stroke and vascular death) when compared to ASA. In the intention to treat analysis, 939 events were observed in the clopidogrel group and 1,020 events with ASA (relative risk reduction (RRR) 8.7%, [95% CI: 0.2 to 16.4]; p = 0.045), which corresponds, for every 1,000 patients treated for 2 years, to 10 [CI: 0 to 20] additional patients being prevented from experiencing a new ischaemic event. Analysis of total mortality as a secondary endpoint did not show any significant difference between clopidogrel (5.8%) and ASA (6.0%).</p><p style="text-align:justify">In a subgroup analysis by qualifying condition (myocardial infarction, ischaemic stroke, and PAD) the benefit appeared to be strongest (achieving statistical significance at p = 0.003) in patients enrolled due to PAD (especially those who also had a history of myocardial infarction) (RRR = 23.7%; CI: 8.9 to 36.2) and weaker (not significantly different from ASA) in stroke patients (RRR = 7.3%; CI: -5.7 to 18.7 [p=0.258]). In patients who were enrolled in the trial on the sole basis of a recent myocardial infarction, clopidogrel was numerically inferior, but not statistically different from ASA (RRR = -4.0 %; CI: -22.5 to 11.7 [p=0.639]). In addition, a subgroup analysis by age suggested that the benefit of clopidogrel in patients over 75 years was less than that observed in patients &le; 75 years.</p><p style="text-align:justify">Since the CAPRIE trial was not powered to evaluate efficacy of individual subgroups, it is not clear whether the differences in relative risk reduction across qualifying conditions are real, or a result of chance.</p><p style="text-align:justify"><em>Acute coronary syndrome</em><br />The CURE study included 12,562 patients with non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), and presenting within 24 hours of onset of the most recent episode of chest pain or symptoms consistent with ischaemia. Patients were required to have either ECG changes compatible with new ischaemia or elevated cardiac enzymes or troponin I or T to at least twice the upper limit of normal. Patients were randomised to clopidogrel (300 mg loading dose followed by 75 mg/day, N=6,259) or placebo (N=6,303), both given in combination with ASA (75-325 mg once daily) and other standard therapies. Patients were treated for up to one year. In CURE, 823 (6.6%) patients received concomitant GPIIb/IIIa receptor antagonist therapy.<br />Heparins were administered in more than 90% of the patients and the relative rate of bleeding between clopidogrel and placebo was not significantly affected by the concomitant heparin therapy.</p><p style="text-align:justify">The number of patients experiencing the primary endpoint [cardiovascular (CV) death, myocardial infarction (MI), or stroke] was 582 (9.3%) in the clopidogrel-treated group and 719 (11.4%) in the placebo-treated group, a 20% relative risk reduction (95% CI of 10%-28%; p=0.00009) for the clopidogrel-treated group (17% relative risk reduction when patients were treated conservatively, 29% when they underwent percutaneous transluminal coronary angioplasty (PTCA) with or without stent and 10% when they underwent coronary artery bypass graft (CABG). New cardiovascular events (primary endpoint) were prevented, with relative risk reductions of 22% (CI: 8.6, 33.4), 32% (CI: 12.8, 46.4), 4% (CI: - 26.9, 26.7), 6% (CI: -33.5, 34.3) and 14% (CI: -31.6, 44.2), during the 0-1, 1-3, 3-6, 6-9 and 9-12 month study intervals, respectively. Thus, beyond 3 months of treatment, the benefit observed in the clopidogrel + ASA group was not further increased, whereas the risk of haemorrhage persisted (see section 4.4).</p><p style="text-align:justify">The use of clopidogrel in CURE was associated with a decrease in the need of thrombolytic therapy (RRR = 43.3%; CI: 24.3%, 57.5%) and GPIIb/IIIa inhibitors (RRR = 18.2%; CI: 6.5%, 28.3%).</p><p style="text-align:justify">The number of patients experiencing the co-primary endpoint (CV death, MI, stroke or refractory ischaemia) was 1035 (16.5%) in the clopidogrel-treated group and 1187 (18.8%) in the placebo- treated group, a 14% relative risk reduction (95% CI of 6%-21%, p=0.0005) for the clopidogrel- treated group. This benefit was mostly driven by the statistically significant reduction in the incidence of MI [287 (4.6%) in the clopidogrel treated group and 363 (5.8%) in the placebo treated group]. There was no observed effect on the rate of rehospitalisation for unstable angina.</p><p style="text-align:justify">The results obtained in populations with different characteristics (e.g. unstable angina or non-Q-wave MI, low to high risk levels, diabetes, need for revascularisation, age, gender, etc.) were consistent with the results of the primary analysis. In particular, in a post-hoc analysis in 2,172 patients (17% of the total CURE population) who underwent stent placement (Stent-CURE), the data showed that clopidogrel compared to placebo, demonstrated a significant RRR of 26.2% favouring clopidogrel for the co-primary endpoint (CV death, MI, stroke) and also a significant RRR of 23.9% for the second co-primary endpoint (CV death, MI, stroke or refractory ischaemia). Moreover, the safety profile of clopidogrel in this subgroup of patients did not raise any particular concern. Thus, the results from this subset are in line with the overall trial results.</p><p style="text-align:justify">The benefits observed with clopidogrel were independent of other acute and long-term cardiovascular therapies (such as heparin/LMWH, GPIIb/IIIa antagonists, lipid lowering medicinal products, beta blockers, and ACE-inhibitors). The efficacy of clopidogrel was observed independently of the dose of ASA (75-325 mg once daily).<br />In patients with acute ST-segment elevation MI, safety and efficacy of clopidogrel have been evaluated in 2 randomised, placebo-controlled, double-blind studies, CLARITY and COMMIT.</p><p style="text-align:justify">The CLARITY trial included 3,491 patients presenting within 12 hours of the onset of a ST elevation MI and planned for thrombolytic therapy. Patients received clopidogrel (300 mg loading dose, followed by 75 mg/day, n=1752) or placebo (n=1739), both in combination with ASA (150 to 325 mg as a loading dose, followed by 75 to 162 mg/day), a fibrinolytic agent and, when appropriate, heparin. The patients were followed for 30 days. The primary endpoint was the occurrence of the composite of an occluded infarct-related artery on the predischarge angiogram, or death or recurrent MI before coronary angiography. For patients who did not undergo angiography, the primary endpoint was death or recurrent myocardial infarction by Day 8 or by hospital discharge. The patient population included 19.7% women and 29.2% patients &ge; 65 years. A total of 99.7% of patients received fibrinolytics (fibrin specific: 68.7%, non-fibrin specific: 31.1%), 89.5% heparin, 78.7% beta blockers, 54.7% ACE inhibitors and 63% statins.</p><p style="text-align:justify">Fifteen percent (15.0%) of patients in the clopidogrel group and 21.7% in the placebo group reached the primary endpoint, representing an absolute reduction of 6.7% and a 36% odds reduction in favor of clopidogrel (95% CI: 24, 47%; p &lt; 0.001), mainly related to a reduction in occluded infarct-related arteries. This benefit was consistent across all prespecified subgroups including patients&rsquo; age and gender, infarct location, and type of fibrinolytic or heparin used.</p><p style="text-align:justify">The 2x2 factorial design COMMIT trial included 45,852 patients presenting within 24 hours of the onset of the symptoms of suspected MI with supporting ECG abnormalities (i.e. ST elevation, ST depression or left bundle-branch block). Patients received clopidogrel (75 mg/day, n=22,961) or placebo (n=22,891), in combination with ASA (162 mg/day), for 28 days or until hospital discharge. The co-primary endpoints were death from any cause and the first occurrence of re- infarction, stroke or death. The population included 27.8% women, 58.4% patients &ge; 60 years (26% &ge; 70 years) and 54.5 % patients who received fibrinolytics.</p><p style="text-align:justify">Clopidogrel significantly reduced the relative risk of death from any cause by 7% (p = 0.029), and the relative risk of the combination of re-infarction, stroke or death by 9% (p = 0.002), representing an absolute reduction of 0.5% and 0.9%, respectively. This benefit was consistent across age, gender and with or without fibrinolytics, and was observed as early as 24 hours.</p><p style="text-align:justify"><em>Atrial fibrillation</em><br />The ACTIVE-W and ACTIVE-A studies, separate trials in the ACTIVE program, included patients with atrial fibrillation (AF) who had at least one risk factor for vascular events. Based on enrollment criteria, physicians enrolled patients in ACTIVE-W if they were candidates for vitamin K antagonist (VKA) therapy (such as warfarin). The ACTIVE-A study included patients who could not receive VKA therapy because they were unable or unwilling to receive the treatment.</p><p style="text-align:justify">The ACTIVE-W study demonstrated that anticoagulant treatment with vitamin K antagonists was more effective than with clopidogrel and ASA.</p><p style="text-align:justify">The ACTIVE-A study (N=7,554) was a multicenter, randomized, double-blind, placebo-controlled study which compared clopidogrel 75 mg/day + ASA (N=3,772) to placebo + ASA (N=3,782). The recommended dose for ASA was 75 to 100 mg/day. Patients were treated for up to 5 years.</p><p style="text-align:justify">Patients randomized in the ACTIVE program were those presenting with documented AF, i.e., either permanent AF or at least 2 episodes of intermittent AF in the past 6 months, and had at least one of the following risk factors: age &ge;75 years or age 55 to 74 years and either diabetes mellitus requiring drug therapy, or documented previous MI or documented coronary artery disease; treated for systemic hypertension; prior stroke, transient ischaemic attack (TIA), or non-CNS systemic embolus; left ventricular dysfunction with left ventricular ejection fraction &lt;45%; or documented peripheral vascular disease. The mean CHADS2 score was 2.0 (range 0-6).</p><p style="text-align:justify">The major exclusion criteria for patients were documented peptic ulcer disease within the previous 6 months; prior intracerebral hemorrhage; significant thrombocytopenia (platelet count &lt; 50 x 109/l); requirement for clopidogrel or oral anticoagulants (OAC); or intolerance to any of the two compounds.</p><p style="text-align:justify">Seventy-three percent (73%) of patients enrolled into the ACTIVE-A study were unable to take VKA due to physician assessment, inability to comply with INR (international normalised ratio) monitoring, predisposition to falling or head trauma, or specific risk of bleeding; for 26% of the patients, the physician&rsquo;s decision was based on the patient&rsquo;s unwillingness to take VKA.</p><p style="text-align:justify">The patient population included 41.8 % women. The mean age was 71 years, 41.6% of patients were &ge;75years. A total of 23.0% of patients received anti-arrhythmics, 52.1% beta-blockers, 54.6% ACE inhibitors, and 25.4% statins.</p><p style="text-align:justify">The number of patients who reached the primary endpoint (time to first occurrence of stroke,MI, non-CNS systemic embolism or vascular death) was 832 (22.1%) in the group treated with clopidogrel + ASA and 924 (24.4%) in the placebo + ASA group (relative risk reduction of 11.1%; 95% CI of 2.4% to 19.1%; p=0.013), primarily due to a large reduction in the incidence of strokes. Strokes occurred in 296 (7.8%) patients receiving clopidogrel + ASA and 408 (10.8%) patients receiving placebo + ASA (relative risk reduction, 28.4%; 95% CI, 16.8% to 38.3%; p=0.00001).</p><p style="text-align:justify"><em>Paediatric population</em><br />In a dose escalation study of 86 neonates or infants up to 24 months of age at risk for thrombosis (PICOLO), clopidogrel was evaluated at consecutive doses of 0.01, 0.1 and 0.2 mg/kg in neonates and infants and 0.15 mg/kg only in neonates. The dose of 0.2 mg/kg achieved the mean percent inhibition of 49.3% (5 &mu;M ADP-induced platelet aggregation) which was comparable to that of adults taking clopidogrel 75 mg/day.</p><p style="text-align:justify">In a randomised, double-blind, parallel-group study (CLARINET), 906 paediatric patients (neonates and infants) with cyanotic congenital heart disease palliated with a systemic-to-pulmonary arterial shunt were randomised to receive clopidogrel 0.2 mg/kg (n=467) or placebo (n=439) along with concomitant background therapy up to the time of second stage surgery. The mean time between shunt palliation and first administration of study medicinal product was 20 days. Approximately 88% of patients received concomitant ASA (range of 1 to 23 mg/kg/day). There was no significant differences between groups in the primary composite endpoint of death, shunt thrombosis or cardiac-related intervention prior to 120 days of age following an event considered of thrombotic nature (89 [19.1%] for the clopidogrel group and 90 [20.5%] for the placebo group) (see section 4.2). Bleeding was the most frequently reported adverse reaction in both clopidogrel and placebo groups; however, there was no significant difference in the bleeding rate between groups. In the long-term safety follow-up of this study, 26 patients with the shunt still in place at one year of age received clopidogrel up to 18 months of age. No new safety concerns were noted during this long- term follow up.</p><p style="text-align:justify">The CLARINET and the PICOLO trials were conducted using a constituted solution of clopidogrel. In a relative bioavailability study in adults, the constituted solution of clopidogrel showed a similar extent and slightly higher rate of absorption of the main circulating (inactive) metabolite compared to the authorised tablet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><em>Absorption</em></p><p style="text-align:justify">After single and repeated oral doses of 75 mg per day, clopidogrel is rapidly absorbed. Mean peak plasma levels of unchanged clopidogrel (approximately 2.2-2.5 ng/ml after a single 75 mg oral dose) occurred approximately 45 minutes after dosing. Absorption is at least 50%, based on urinary excretion of clopidogrel metabolites.</p><p style="text-align:justify"><em>Distribution</em></p><p style="text-align:justify">Clopidogrel and the main circulating (inactive) metabolite bind reversibly in vitro to human plasma proteins (98% and 94% respectively). The binding is non-saturable in vitro over a wide concentration range.</p><p style="text-align:justify"><em>Biotransformation</em></p><p style="text-align:justify">Clopidogrel is extensively metabolised by the liver. In vitro and in vivo, clopidogrel is metabolised according to two main metabolic pathways: one mediated by esterases and leading to hydrolysis into its inactive carboxylic acid derivative (85% of circulating metabolites), and one mediated by multiple cytochromes P450. Clopidogrel is first metabolised to a 2-oxo-clopidogrel intermediate metabolite. Subsequent metabolism of the 2-oxoclopidogrel intermediate metabolite results in formation of the active metabolite, a thiol derivative of clopidogrel. In vitro, this metabolic pathway is mediated by CYP3A4, CYP2C19, CYP1A2 and CYP2B6. The active thiol metabolite which has been isolated in vitro, binds rapidly and irreversibly to platelet receptors, thus inhibiting platelet aggregation.</p><p style="text-align:justify">The Cmax of the active metabolite is twice as high following a single 300-mg clopidogrel loading dose as it is after four days of 75-mg maintenance dose. Cmax occurs approximately 30 to 60 minutes after dosing.</p><p style="text-align:justify"><em>Elimination</em></p><p style="text-align:justify">Following an oral dose of 14C-labelled clopidogrel in man, approximately 50% was excreted in the urine and approximately 46% in the faeces in the 120-hour interval after dosing. After a single oral dose of 75 mg, clopidogrel has a half-life of approximately 6 hours. The elimination half-life of the main circulating (inactive) metabolite was 8 hours after single and repeated administration.</p><p style="text-align:justify"><em>Pharmacogenetics</em></p><p style="text-align:justify">CYP2C19 is involved in the formation of both the active metabolite and the 2-oxo-clopidogrel intermediate metabolite. Clopidogrel active metabolite pharmacokinetics and antiplatelet effects, as measured by ex vivo platelet aggregation assays, differ according to CYP2C19 genotype.</p><p style="text-align:justify">The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and CYP2C19*3 alleles are nonfunctional. The CYP2C19*2 and CYP2C19*3 alleles account for the majority of reduced function alleles in Caucasian (85%) and Asian (99%) poor metabolisers. Other alleles associated with absent or reduced metabolism are less frequent and include CYP2C19*4, *5,*6, *7, and *8. A patient with poor metaboliser status will possess two loss-offunction alleles as defined above. Published frequencies for the poor CYP2C19 metaboliser genotypes are approximately 2% for Caucasians, 4% for Blacks and 14% for Chinese. Tests are available to determine a patient&acute;s CYP2C19 genotype.</p><p style="text-align:justify">A crossover study in 40 healthy subjects, 10 each in the four CYP2C19 metaboliser groups (ultrarapid, extensive, intermediate and poor), evaluated pharmacokinetic and antiplatelet responses using 300 mg followed by 75 mg/day and 600 mg followed by 150 mg/day, each for a total of 5 days (steady state). No substantial differences in active metabolite exposure and mean inhibition of platelet aggregation (IPA) were observed between ultrarapid, extensive and intermediate metabolisers. In poor metabolisers, active metabolite exposure was decreased by 63-71% compared to extensive metabolisers. After the 300 mg/75 mg dose regimen, antiplatelet responses were decreased in the poor metabolisers with mean IPA (5 &mu;M ADP) of 24% (24 hours) and 37% (Day 5) as compared to IPA of 39% (24 hours) and 58% (Day 5) in the extensive metabolisers and 37% (24 hours) and 60% (Day 5) in the intermediate metabolisers.</p><p style="text-align:justify">When poor metabolisers received the 600 mg/150 mg regimen, active metabolite exposure was greater than with the 300 mg/75 mg regimen. In addition, IPA was 32% (24 hours) and 61% (Day 5), which were greater than in the poor metabolisers receiving the 300 mg/75 mg regimen, and were similar to the other CYP2C19 metaboliser groups receiving the 300 mg/75 mg regimen. An appropriate dose regimen for this patient population has not been established in clinical outcome trials.</p><p style="text-align:justify">Consistent with the above results, in a meta-analysis including 6 studies of 335 clopidogrel-treated subjects at steady state, it was shown that active metabolite exposure was decreased by 28% for intermediate metabolisers, and 72% for poor metabolisers while platelet aggregation inhibition (5&mu;M ADP) was decreased with differences in IPA of 5.9% and 21.4%, respectively, when compared to extensive metabolisers.</p><p style="text-align:justify">The influence of CYP2C19 genotype on clinical outcomes in patients treated with clopidogrel has not been evaluated in prospective, randomised, controlled trials. There have been a number of retrospective analyses, however, to evaluate this effect in patients treated with clopidogrel for whom there are genotyping results: CURE (n=2721), CHARISMA (n=2428), CLARITY-TIMI 28 (n=227), TRITON-TIMI 38 (n=1477), and ACTIVE-A (n=601), as well as a number of published cohort studies.</p><p style="text-align:justify">In TRITON-TIMI 38 and 3 of the cohort studies (Collet, Sibbing, Giusti) the combined group of patients with either intermediate or poor metaboliser status had a higher rate of cardiovascular<br />events (death, myocardial infarction, and stroke) or stent thrombosis compared to extensive metabolisers.</p><p style="text-align:justify">In CHARISMA and one cohort study (Simon), an increased event rate was observed only in poor metabolisers when compared to extensive metabolisers.</p><p style="text-align:justify">In CURE, CLARITY, ACTIVE-A and one of the cohort studies (Trenk), no increased event rate was observed based on metaboliser status.<br />None of these analyses were adequately sized to detect differences in outcome in poor metabolizers.</p><p style="text-align:justify"><em>Special populations</em></p><p style="text-align:justify">The pharmacokinetics of the active metabolite of clopidogrel is not known in these special populations.</p><p style="text-align:justify"><em>Renal impairment</em></p><p style="text-align:justify">After repeated doses of 75 mg clopidogrel per day in subjects with severe renal disease (creatinine clearance from 5 to 15 ml/min), inhibition of ADP-induced platelet aggregation was lower (25%) than that observed in healthy subjects, however, the prolongation of bleeding time was similar to that seen in healthy subjects receiving 75 mg of clopidogrel per day. In addition, clinical tolerance was good in all patients.</p><p style="text-align:justify"><em>Hepatic impairment</em></p><p style="text-align:justify">After repeated doses of 75 mg clopidogrel per day for 10 days in patients with severe hepatic impairment, inhibition of ADP-induced platelet aggregation was similar to that observed in healthy subjects. The mean bleeding time prolongation was also similar in the two groups.</p><p style="text-align:justify"><em>Race</em></p><p style="text-align:justify">The prevalence of CYP2C19 alleles that result in intermediate and poor CYP2C19 metabolism differs according to race/ethnicity (see Pharmacogenetics). From literature, limited data in Asian populations are available to assess the clinical implication of genotyping of this CYP on clinical outcome events.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">During non clinical studies in rat and baboon, the most frequently observed effects were liver changes. These occurred at doses representing at least 25 times the exposure seen in humans receiving the clinical dose of 75 mg/day and were a consequence of an effect on hepatic metabolising enzymes. No effect on hepatic metabolising enzymes was observed in humans receiving clopidogrel at the therapeutic dose.</p><p style="text-align:justify">At very high doses, a poor gastric tolerability (gastritis, gastric erosions and/or vomiting) of clopidogrel was also reported in rat and baboon.</p><p style="text-align:justify">There was no evidence of carcinogenic effect when clopidogrel was administered for 78 weeks to mice and 104 weeks to rats when given at doses up to 77 mg/kg per day (representing at least 25 times the exposure seen in humans receiving the clinical dose of 75 mg/day).</p><p style="text-align:justify">Clopidogrel has been tested in a range of in vitro and in vivo genotoxicity studies, and showed no genotoxic activity.</p><p style="text-align:justify">Clopidogrel was found to have no effect on the fertility of male and female rats and was not teratogenic in either rats or rabbits. When given to lactating rats, clopidogrel caused a slight delay in the development of the offspring. Specific pharmacokinetic studies performed with radiolabelled clopidogrel have shown that the parent compound or its metabolites are excreted in the milk.</p><p style="text-align:justify">Consequently, a direct effect (slight toxicity), or an indirect effect (low palatability) cannot be excluded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Core:</strong></p><p>Lactose anhydrous, Microcrystalline cellulose, Crospovidone Type A Glycerol dibehenate, Talc</p><p><strong>Coating:</strong></p><p>Polyvinyl alcohol Talc, Macrogol 3350, Lecithin (soya oil) (E322), Titanium dioxide (E171), Iron oxide red (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blister packs of Aluminium/Aluminium.</p><p><em>Pack sizes:</em><br />Blisters: 30 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AJA Pharmaceutical Industries Company, Ltd.
Hail Industrial City MODON, Street No 32
PO Box 6979 , Hail 5514
Kingdom of Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>